Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors represent both valid and effective options to enhance weight management and HbA1c control in subjects with PWS [44, 56]. Here, GLP1R is linked to Prader-Willi syndrome.